{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ+Maintenance&page=2", "query": { "intervention": "TMZ Maintenance", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ+Maintenance&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T09:21:34.247Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06991101", "title": "Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Brain Cancer", "Glioblastoma Multiforme", "Glioblastoma Multiforme of Brain", "Glioblastoma Multiforme, Adult", "MGMT-Unmethylated Glioblastoma", "MGMT-Methylated Glioblastoma" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2025-12-03", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 2, "location_summary": "Miami, Florida • New York, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06991101" }, { "nct_id": "NCT04047706", "title": "Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "IDO1 Inhibitor BMS-986205 25mg", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "IDO1 Inhibitor BMS-986205 50 mg", "type": "DRUG" }, { "name": "IDO1 Inhibitor BMS-986205 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-08-13", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047706" }, { "nct_id": "NCT00458601", "title": "Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "CDX-110 with GM-CSF", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2007-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 34, "location_summary": "Orange, California • San Francisco, California • Stanford, California + 22 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458601" }, { "nct_id": "NCT02546102", "title": "Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "ICT-107", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precision Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2024-12", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-04-03", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546102" }, { "nct_id": "NCT03363659", "title": "Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Disulfiram", "type": "DRUG" }, { "name": "Copper gluconate", "type": "DIETARY_SUPPLEMENT" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-03-28", "completion_date": "2022-01-13", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03363659" }, { "nct_id": "NCT02254954", "title": "Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Macitentan in combination with RT and TMZ", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actelion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-01-08", "completion_date": "2016-09-29", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02254954" }, { "nct_id": "NCT01236560", "title": "Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Brain Stem Glioma", "Cerebral Astrocytoma", "Childhood Cerebellar Anaplastic Astrocytoma", "Childhood Cerebral Anaplastic Astrocytoma", "Childhood Spinal Cord Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 101, "start_date": "2011-01-26", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 124, "location_summary": "Birmingham, Alabama • Downey, California • Loma Linda, California + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01236560" }, { "nct_id": "NCT00960492", "title": "Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Giant Cell Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "XL184", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2009-09", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2014-09-22", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 8, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960492" }, { "nct_id": "NCT02337426", "title": "Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Brain Glioblastoma", "Adult Giant Cell Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "Dimethyl Fumarate", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-02-13", "completion_date": "2017-11-09", "has_results": false, "last_update_posted_date": "2019-06-28", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02337426" }, { "nct_id": "NCT01837862", "title": "A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pilomyxoid Astrocytoma", "Pilocytic Astrocytoma", "Glioma, Astrocytic", "Optic Nerve Glioma", "Pleomorphic Xanthoastrocytoma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Gliosarcoma", "Diffuse Intrinsic Pontine Glioma", "DIPG", "Low-grade Glioma", "Brainstem Glioma" ], "interventions": [ { "name": "Mebendazole", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie Krystal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 10, "start_date": "2013-10-22", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-20T09:21:34.247Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837862" } ] }